16:02 Dec 20
Indegene Ltd.
Sector Pharmaceuticals & Biotechnology
Industry Pharmaceuticals
Indegene Ltd.
Industry Pharmaceuticals
16:02 Dec 20
Quality
57/100
High Financial Strength
Valuation
27/100
Expensive Valuation
Technical
32/100
Technically Bearish
Strength
7
Weakness
1
Opportunity
1
Threats
2
23.56 %
ROE %
13.22 %
ROA %
15.58
EPS
64.37
BVPS
13.00 %
Net Profit Margin
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM 2024 | ||
|---|---|---|---|---|---|---|
| Net Sales | 966.27 | 1664.61 | 2306.13 | 2589.6 | 2709.71 | |
| Operating Expenses + | 735.74 | 1377.69 | 1909.91 | 2084.2 | 2167.2 | |
| Raw Material | 0 | 0 | 0 | 0 | 0 | |
| Increase Decrease in Cost | 0 | 0 | 0 | 0 | 0 | |
| Other Manufacturing Expense | 0 | 0 | 0 | 0 | 0 | |
| Employee Cost | 535.6 | 1014.34 | 1464.76 | 1651.6 | 1727.64 | |
| Miscellaneous Expenses | 200.14 | 363.35 | 445.15 | 432.6 | 439.56 | |
| Operating Profit | 230.53 | 286.92 | 396.22 | 505.4 | 542.51 | |
| Other Income | 30.65 | 25.89 | 57.96 | 76.3 | 80.14 | |
| Depreciation | 25.55 | 33.45 | 59.81 | 76.1 | 75.63 | |
| Interest | 6.96 | 5.96 | 31.33 | 49.4 | 40.21 | |
| Profit before tax and exceptio.. | 228.67 | 273.4 | 363.05 | 456.2 | 506.81 | |
| Exceptional Items | 2.99 | -46.9 | 0 | 2.4 | 2.4 | |
| PBT | 231.66 | 226.5 | 363.05 | 458.6 | 504.41 | |
| Provision for Taxation | 45.78 | 63.68 | 96.95 | 121.9 | 136.5 | |
| Net Profit | 149.61 | 162.82 | 266.1 | 336.7 | 372.7 | |
| NET Profit after MI | 149.4 | 164.76 | 266.1 | 336.7 | 372.7 | |
| EPS | 7.56 | 7.5 | 12.03 | 15.19 | 192.47 | |
| Operating Profit Margin (%) | 23.86 | 17.24 | 17.18 | 19.52 | 20.02 | |
| Net Profit Margin (%) | 15.46 | 9.9 | 11.54 | 13 | 13.75 |
ShareHolding
Promoter
FII
Public
Mutual Funds
Other Institutions
All Data in Percentage (%)
| Sep 24 | |
|---|---|
| Promoter | 0.00 |
| FII | 4.80 |
| MF | 1.60 |
| Public | 92.00 |
| Others | 0.00 |
| Others | 1.60 |
| Shareholder | Shares | Holding % |
|---|
Download Our App On:
